Deciphera Pharmaceuticals, Inc.(DCPH)

Description: Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.

---

Keywords: Medicine Cancer Biopharmaceutical Drugs Immune System Cancer Treatment Clinical Development Antineoplastic Drugs Gastrointestinal Glioblastoma Blastoma Protein Kinase Inhibitor Targeted Therapy Tyrosine Kinase Receptors Platelet Glioblastoma Multiforme Mastocytosis Gastrointestinal Stromal Tumors Systemic Mastocytosis Gastrointestinal Stromal Tumor Treatment For Cancer

---

Home Page: www.deciphera.com

DCPH Technical Analysis

200 Smith Street
Waltham, MA 02451
United States
Phone: 781 209 6400

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)